Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 8:50 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2449–2472 of 2,912 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Capsules Clear all

Conditions: Leiomyoma, Uterine, Leiomyoma, Fibroid, Fibroid Uterus
Interventions: Letrozole 2.5mg, Placebo; Drug · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 21 Years to 53 Years · Female only
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 5
States / cities: Los Angeles, California • San Francisco, California • Rochester, Minnesota + 2 more

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: HEC585; Drug
Lead sponsor: Sunshine Lake Pharma Co., Ltd.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 136 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Pulmonary Hypertension Secondary, Heart Failure
Interventions: Sodium Nitrite, Placebo Oral Capsule; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Major Depressive Disorder
Interventions: Placebo, Cariprazine; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 819 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 39
States / cities: Garden Grove, California • National City, California • Oceanside, California + 34 more

Conditions: Interstitial Cystitis, Painful Bladder Syndrome
Interventions: PD 0299685 at 15mg BID, PD 0299685 at 30mg BID, placebo for PD 0299685; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 23
States / cities: Mobile, Alabama • Goodyear, Arizona • Litchfield Park, Arizona + 20 more

Conditions: Hypothyroidism
Interventions: Armour Thyroid, Levothyroxine; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 2,701 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 134
States / cities: Birmingham, Alabama • Bonita, California • Burbank, California + 110 more

Conditions: Alzheimer Disease
Interventions: Buntanetap/Posiphen, Placebo; Drug
Lead sponsor: Annovis Bio Inc.; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 351 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 54
States / cities: Gilbert, Arizona • Phoenix, Arizona • Fort Smith, Arkansas + 42 more

Conditions: Renal Insufficiency, Heart Failure
Interventions: Tonapofylline, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 30
States / cities: Huntsville, Alabama • Mobile, Alabama • Scottsdale, Arizona + 25 more

Conditions: Urinary Incontinence
Interventions: Litoxetine, placebo; Drug
Lead sponsor: Ixaltis SA; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Williamsville, New York

Conditions: Gout, Hyperuricemia
Interventions: LC350189 formulated capsule, Placebo; Drug
Lead sponsor: LG Chem; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 34
States / cities: Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 28 more

Conditions: Psoriasis
Interventions: Cap SRT2104, Tab SRT2104 slow release, Tab SRT2104 intermediate release, Tab SRT2104 fast release, Selected formulations of SRT2104 from Part 1, Selected formulations of SRT2104 from Part 1 single alternative dose; Drug
Lead sponsor: Sirtris, a GSK Company; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Prostate Cancer
Interventions: AAA817, ARPI, Standard of Care; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 940 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 42
States / cities: Homewood, Alabama • Tucson, Arizona • Orange, California + 37 more

Conditions: Bipolar Disorder
Interventions: MCN36 (nutritional supplement), Placebo; Drug
Lead sponsor: University of Calgary; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: San Diego, California

Conditions: Advanced, Metastatic Breast Cancer
Interventions: Ribociclib, Letrozole, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 668 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 73
States / cities: Chandler, Arizona • Sedona, Arizona • Fayetteville, Arkansas + 62 more

Conditions: Hypertension, Stage 2 Hypertension, Diabetes
Interventions: Valturna, Amlodipine, Chlorthalidone, Placebo of Valturna Tablet, Placebo Capsule; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 975 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 95
States / cities: Athens, Alabama • Florence, Alabama • Huntsville, Alabama + 78 more

Conditions: Schizophrenia
Interventions: Sildenafil; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: NSAID-induced Gastroduodenal Injury, Ulcers, Rheumatoid Arthritis, Osteoarthritis
Interventions: Cobiprostone, Placebo, Non-steroidal anti-inflammatory drug; Drug
Lead sponsor: Sucampo Pharma Americas, LLC; Industry
Eligibility: 40 Years to 70 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 19
States / cities: Phoenix, Arizona • Chula Vista, California • Loma Linda, California + 16 more

Conditions: Depression
Interventions: S-adenosyl-l-methionine, Escitalopram, Placebo; Drug
Lead sponsor: Maurizio Fava, MD; Other
Eligibility: 18 Years to 80 Years
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 2
States / cities: Boston, Massachusetts • Providence, Rhode Island

Conditions: Diabetic Peripheral Neuropathic Pain
Interventions: Suzetrigine, Placebo (matched to SUZ), Pregabalin, Placebo (matched to Pregabalin); Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 76
States / cities: Anniston, Alabama • Birmingham, Alabama • Daphne, Alabama + 68 more

Conditions: Acute Coronary Syndrome
Interventions: Polypill; Combination Product
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 4
States / cities: Dallas, Texas

Conditions: Pharmacokinetics
Interventions: TAK-875 and Glimepiride; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 68 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Disorder Related to Lung Transplantation, Chronic Lung Allograft Dysfunction
Interventions: Pirfenidone Capsule, Placebo Capsule; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Interstitial Cystitis, Chronic Interstitial Cystitis, Bladder Pain Syndrome
Interventions: Desert Harvest Aloe Vera Capsules, Placebo Capsules; Drug · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Rhinitis, Allergic, Perennial and Seasonal
Interventions: FPNS, FPNS Placebo, Cetirizine, Cetirizine Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 682 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 31
States / cities: Little Rock, Arkansas • Denver, Colorado • Aventura, Florida + 27 more

Search by objective public record fields.

Prescription of Letrozole for Uterine Myoma

The Safety, Tolerability and Pharmacokinetic Study of HEC585 in Healthy Male and Female Subjects

Oral Nitrite in Patients With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction

Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder

An Effectiveness And Safety Study Of PD 0299685 For The Treatment Of Symptoms Associated With Interstitial Cystitis

A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants

A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD

Oral Tonapofylline (BG9928) in Patients With Heart Failure and Renal Insufficiency

DBPC Trial to Evaluate the Safety, Tolerability and Efficacy of Oral Litoxetine in Subjects With Urinary Incontinence

A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia

A Study to Assess the Relative Bioavailability of New Oral Formulations of SRT2104 in Healthy Male Volunteers

Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

Clinical Trial of a Nutritional Supplement in Adults With Bipolar Disorder

Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer

Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes

A Placebo-Controlled Single-Dose Trial of Sildenafil in Schizophrenia

Cobiprostone Prevention of NSAID-induced Gastroduodenal Injury

Safety and Effectiveness of S-adenosyl-l-methionine (SAMe) for the Treatment of Major Depression

Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy

A Polypill for Acute Coronary Syndrome

TAK-875 Glimepiride Drug-Interaction Study

Studying the Treatment Effect of Pirfenidone in Chronic Lung Allograft Dysfunction (STOP-CLAD)

Safety and Efficacy of Aloe Vera in the Management of the Symptoms of Interstitial Cystitis

A Comparator Study of Fluticasone Propionate Nasal Spray Verses (vs) Cetirizine in the Treatment of Seasonal Allergic Rhinitis